Literature DB >> 10387091

Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin.

C Boudier1, M Cadène, J G Bieth.   

Abstract

Oxidation of mucus proteinase inhibitor (MPI) transforms Met73, the P'1 residue of its active center into methionine sulfoxide and lowers its affinity for neutrophil elastase [Boudier, C., and Bieth, J. G. (1994) Biochem. J. 303, 61-68]. Here, we show that the oxidized inhibitor has also a decreased affinity for neutrophil cathepsin G and pancreatic chymotrypsin. The Ki of the oxidized MPI-cathepsin G complex (1.2 microM) is probably too high to be compatible with significant inhibition of cathepsin G in inflammatory lung secretions. Stopped-flow kinetics shows that, within the inhibitor concentration range used, the mechanism of inhibition of cathepsin G and chymotrypsin by oxidized MPI is consistent with a one-step reaction, [equation in text] whereas the inhibition of elastase takes place in two steps, [equation in text]. Heparin, which accelerates the inhibition of the three proteinases by native MPI, also favors their interaction with oxidized MPI. Flow calorimetry shows that heparin binds oxidized MPI with Kd, Delta H degrees, and Delta S degrees values close to those reported for native MPI. In the presence of heparin, oxidized MPI inhibits cathepsin G via a two-step reaction characterized by Ki = 0.22 microM, k2 = 0.1 s-1, k-2 = 0.023 s-1, and Ki = 42 nM. Under these conditions, in vivo inhibition of cathepsin G is again possible. Heparin also improves the inhibition of chymotrypsin and elastase by oxidized MPI by increasing their kass or k2/Ki and decreasing their Ki. Our data suggest that oxidation of MPI during chronic bronchitis may lead to cathepsin G-mediated lung tissue degradation and that heparin may be a useful adjuvant of MPI-based therapy of acute lung inflammation in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10387091     DOI: 10.1021/bi9828526

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma.

Authors:  Christian Cordes; Robert Häsler; Christian Werner; Tibor Görögh; Christoph Röcken; Lena Hebebrand; W Martin Kast; Markus Hoffmann; Stefan Schreiber; Petra Ambrosch
Journal:  Int J Oncol       Date:  2011-04-14       Impact factor: 5.650

2.  miRNA-expression in tonsillar squamous cell carcinomas in relation to HPV infection and expression of the antileukoproteinase SLPI.

Authors:  Elgar Susanne Quabius; Immanuel Merz; Tibor Görögh; Jürgen Hedderich; Jochen Haag; Christoph Röcken; Petra Ambrosch; Markus Hoffmann
Journal:  Papillomavirus Res       Date:  2017-06-16

3.  Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-κB and Akt pathways.

Authors:  Yu Jin; Yuexiu Li; Xin Wang; Ya Yang
Journal:  Cancer Cell Int       Date:  2019-08-23       Impact factor: 5.722

4.  Effective DNA inhibitors of cathepsin g by in vitro selection.

Authors:  Barbara Gatto; Elena Vianini; Lorena Lucatello; Claudia Sissi; Danilo Moltrasio; Rodolfo Pescador; Roberto Porta; Manlio Palumbo
Journal:  Int J Mol Sci       Date:  2008-06-20       Impact factor: 6.208

5.  Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor.

Authors:  Markus Hoffmann; Elgar S Quabius; Silke Tribius; Lena Hebebrand; Tibor Görögh; Gordana Halec; Tomas Kahn; Jürgen Hedderich; Christoph Röcken; Jochen Haag; Tim Waterboer; Markus Schmitt; Anna R Giuliano; W Martin Kast
Journal:  Oncol Rep       Date:  2013-03-05       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.